InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
ICP-B794 is developed from InnoCare's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients.
Share
ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others.
Currently, there are no B7-H3 targeted therapies approved for marketing globally. B7-H3 is a type I transmembrane protein that is highly expressed in a variety of solid tumors. Due to its specific expression in tumor cells, it is considered a highly promising anti-tumor target.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "ICP-B794 is developed from the Company's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology."
With ongoing efforts to address the growing needs in solid tumors, InnoCare is committed to building a competitive drug portfolio aimed at treating a broad range of solid tumor indications. The Company is expanding the scope of its pipeline through a combination of targeted therapies, immune-oncology approaches, and cutting-edge ADC technology. The R&D team is focused on discovering and developing novel platforms that target various solid tumors, utilizing innovative technologies to identify and advance potential drug candidates that offer significant clinical benefits. InnoCare's proprietary ADC technology platform, alongside promising precision medicine candidates like TRK inhibitor zurletrectinib (ICP-723), positions the Company to establish a strong presence in the field of solid tumor treatment.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Game-Changing HSA Reforms Just Passed—Here's What It Means for Healthcare
SAN FRANCISCO--(BUSINESS WIRE)--Today, Lively, Inc. marks the signature of the 'One Big Beautiful Bill' (OBBB) into law, a major bill that expands access and flexibility for Health Savings Accounts (HSAs). Under the new law, millions of Americans enrolled in Bronze or Catastrophic ACA plans are now eligible to contribute to HSAs starting January 1, 2026, and key innovations like telehealth services and Direct Primary Care are officially HSA-qualified expenses. Game-Changing HSA Reforms Just Passed—Here's What It Means for Healthcare: Landmark legislation enables HSA use with Bronze/Catastrophic ACA plans, telehealth, and direct primary care—bringing healthcare savings into the modern era. Share Lively, a top-rated health and lifestyle benefits platform* known for building the modern Health Savings Account (HSA), is uniquely positioned to support individuals, employers, and brokers navigating this new era. Lively's platform already connects with over 95% of U.S. health plans and integrates seamlessly with Direct Primary Care models and virtual-first providers. 'In a world of rising out-of-pocket costs, HSAs are the most powerful way to take control of US consumer healthcare finances. This isn't just a policy shift—it's a redefinition of how Americans can save, spend, and stay healthy," said Alex Cyriac, CEO and co-founder of Lively. 'At Lively, we've built a platform that's flexible, intelligent, and ready for this next generation of benefits.' What's Changing: HSA Eligibility Opens for Millions of Americans: Enrollees in Bronze and Catastrophic ACA plans are now eligible and can contribute to HSAs. Modern Care Models Included: HSA funds can be used for Direct Primary Care arrangements. Telehealth Flexibility Made Permanent: First-dollar coverage for telehealth services no longer disqualifies HSA status. How Lively Helps: No Hidden Fees - Your healthcare shouldn't come at a hidden cost — Lively HSAs are free for individuals and families. Get Started in Minutes: Confirm your eligibility and open an HSA account instantly. Smart Claim Sync: Automatically syncs with employee health plan data, including high-deductible, Bronze, and Catastrophic plans. Built for Innovation: Already supports virtual-first, Direct Primary Care (DPC), and hybrid health plan designs. About Lively Lively is the health and lifestyle benefits provider that gets it right. Our solutions are designed to take the guesswork out of managing benefits and drive efficiency for HR teams. Our innovative platform combines robust features with unparalleled service, to make maximizing your benefits as simple as it should be. Lively currently offers HSA, FSA, HRA, COBRA, Direct Bill, Commuter, Lifestyle Spending Accounts, and Medical Travel Accounts.
Business Wire
3 hours ago
- Business Wire
OLO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olo Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Olo Inc. (NYSE: OLO) to Thoma Bravo. Under the terms of the proposed transaction, shareholders of Olo will receive $10.25 in cash for each share of Olo that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
7 hours ago
- Business Wire
Haleon Breaks Ground on new £130m Global Oral Health Innovation Centre
LONDON--(BUSINESS WIRE)--This week, Haleon, a global leader in consumer health and maker of leading brands such as Sensodyne, parodontax and Polident, broke ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This state-of-the-art facility will enhance Haleon's science capabilities, accelerate innovation, and serve as a centre of excellence for global oral health research. The groundbreaking ceremony, attended by UK Minister Baroness Jones, marks an important step in Haleon's ambition to reach one billion more consumers by 2030, by strengthening its oral health R&D capabilities to put health in more hands globally. Set to become the R&D epicentre for Haleon's oral health portfolio, the centre will be a dynamic hub for pioneering research, product innovation, commercial and supply chain excellence, and cross-functional collaboration. Equipped with the latest technology and global expertise, the centre will feature a cutting-edge digital immersive room designed to unlock value at pace through real-time collaboration with Haleon's manufacturing site in Levice. At the heart of the building, the atrium will create a vibrant hub for teamwork and co-creation, bringing leading expertise together to develop solutions that address unmet oral health needs for consumers around the world. Designed with sustainability at its core, the site has recently achieved a BREEAM® Outstanding rating, recognising its exceptional commitment to sustainability at Phase 1 in the design stage. Franck Riot, Chief R&D Officer, Haleon, said:" We are excited to break ground on our Global Oral Health Innovation Centre - a major investment reflecting our commitment to advancing science and innovation. This powerhouse for oral health research will strengthen Haleon's R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world. ' Chancellor of the Exchequer, Rachel Reeves MP, said: 'This exciting milestone is another demonstration of the strength of the UK life sciences sector, a key pillar to our Industrial Strategy. Under this government Britain is open for business, and through our Plan for Change we're delivering more investment, more jobs and more money in people's pockets.' UK Minister for Technology, Baroness Jones, said: 'Haleon is breaking ground on a new centre that will place the UK at the forefront of innovation to improve everyone's oral health - which we know is important to our wider health, and to children's development. This centre, and the substantial investment behind it, is proof that the UK's world-leading life sciences sector is the place to be to grow businesses and work on fresh ideas to transform healthcare. Leveraging these strengths will lead to the long-term economic growth that will help us deliver on our Plan for Change.' Jayant Singh, Global Category Lead, Oral Health, Haleon, said:" With oral diseases affecting nearly half the world's population, this marks an exciting step forward in our mission to put health in more hands for millions across the world. This centre will play a key role in harnessing the full potential of science and innovation across our oral health portfolio. ' About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
